Clinical Overview

Encephalitis lethargica (EL) is a rare, potentially devastating neuroinflammatory syndrome characterized by an acute or subacute onset of febrile illness followed by profound alterations in consciousness, sleep-wake cycles, and motor control. While historically associated with the global pandemic of 1917–1928, contemporary clinical interest has been revitalized by the recognition of Autoimmune Encephalitis (AE) syndromes that mimic the classic presentation of EL.

The condition is categorized into two distinct phases:

1. Acute/Subacute Phase: Characterized by “lethargic” symptoms, including hypersomnolence, akinetic mutism, and psychiatric disturbances.
2. Chronic/Sequelae Phase: Characterized by the development of Post-Encephalitic Parkinsonism (PEP), a devastating movement disorder resulting from neurodegeneration in the basal ganglia.

Pathophysiology: The Autoimmune Hypothesis

The etiology of the historical EL epidemic remains debated, but modern neuroimmunology provides a compelling framework. Current evidence suggests that EL is likely an autoimmune encephalopathy triggered by molecular mimicry.

It is hypothesized that an infectious agent (potentially a virus such as influenza or another respiratory pathogen) triggers the production of antibodies against neuronal surface antigens. In contemporary cases, clinicians must differentiate EL from established autoimmune encephalitis syndromes, such as:

• Anti-NMDAR Encephalitis: Often presenting with psychiatric symptoms, seizures, and orofacial dyskinesias.
• Anti-LGI1 Encephalitis: Characterized by faciobrachial dystonic seizures and cognitive decline.

The “Parkinsonian” sequelae suggest that the inflammatory process specifically targets the nigrostriatal pathway, leading to profound dopaminergic depletion in the substantia nigra pars compacta, similar to idiopathic Parkinson’s disease but with a more rapid and aggressive clinical course.

Clinical Presentation & Diagnostic Criteria

1. Acute Phase (The “Lethargic” Presentation)

Patients typically present with an influenza-like prodrome (fever, headache, myalgia) followed by:

• Neuropsychiatric Symptoms: Rapid onset of psychosis, delusions, hallucinations, and profound personality changes.
• Sleep-Wake Dysregulation: Severe hypersomnolence or “sleep inversion” (reversed circadian rhythms).
• Akinetic Mutism: A state where the patient is awake but unable to move or speak purposefully—a critical clinical distinction from vegetative states.
• Oculomotor Abnormalities: Ophthalmoplegia, nystagmus, or aberrant eye movements.
• Pyramidal/Extrapyramidal Signs: Neck rigidity (meningismus), tremors, and muscle weakness.

2. Chronic Phase (Post-Encephalitic Parkinsonism)

As the neuroinflammatory process transitions to neurodegeneration, patients develop:

• Parkinsonian Features: Bradykinesia, resting tremor, postural instability, and “masked facies” (hypomimia).
• Secondary Dementia: Cognitive decline characterized by slowed processing and executive dysfunction.

Diagnostic Criteria (Refined)

Diagnosis is primarily clinical and requires the exclusion of infectious encephalitis (e.g., HSV-1), metabolic encephalopathy, and neoplastic processes via MRI and CSF analysis. A modern diagnostic framework includes:

1. Acute/Subacute onset of febrile illness.
2. Presence of at least three of the following: Hypersomnolence, ophthalmoplegia, psychiatric disturbances, motor dysfunction (parkinsonism/dystonia), or altered consciousness.
3. Exclusion of other etiologies via neuroimaging (showing characteristic T2/FLAIR hyperintensities in basal ganglia) and CSF studies.

Management Strategies

Because the underlying mechanism is increasingly viewed as immune-mediated, management must be aggressive during the acute phase to mitigate long-term neurological damage.

1. Immunomodulatory Therapy (First-Line)

• Corticosteroids: High-dose intravenous methylprednisolone is indicated to reduce neuroinflammation. Response in the acute phase can be a diagnostic clue.
• Intravenous Immunoglobulin (IVIG): Used as an alternative or adjunct to steroids to neutralize pathogenic autoantibodies.
• Plasmapheresis (Plasma Exchange): Indicated in severe, refractory cases of autoimmune encephalitis to rapidly remove circulating antibodies.

2. Symptomatic Management (Chronic Phase)

• Dopaminergic Replacement: Levodopa (L-DOPA) is the mainstay for treating Parkinsonian symptoms.
  • Clinical Pearl: While L-DOPA often provides dramatic, albeit transient, relief in the early stages of PEP, long-term efficacy is often limited by the development of dyskinesias and rapid “wearing-off” effects due to the severity of the underlying neurodegeneration.
• Psychiatric Management: Atypical antipsychotics may be required for psychotic symptoms, though clinicians must exercise caution regarding extrapyramidal side effects (EPS) which can exacerbate Parkinsonian symptoms.

Prognosis

The prognosis is highly variable and depends heavily on the timing of intervention.

• Acute Recovery: Some patients achieve near-complete recovery if treated aggressively during the inflammatory phase.
• Chronic Morbidity: For those progressing to PEP, the prognosis is guarded. The resulting “secondary dementia” and motor disability are often profound, leading to significant loss of autonomy and increased mortality.

Clinical Summary for the Practitioner

When encountering a patient with an unexplained rapid-onset encephalopathy characterized by sleep disturbances and movement disorders, clinicians should not dismiss it as a historical relic. Instead, treat it as a high-stakes autoimmune neuroinflammatory emergency. Early initiation of immunomodulatory therapy is critical to preventing irreversible neurodegeneration and the subsequent development of Parkinsonism.